Delta Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$385K Sell
863
-9
-1% -$4.2K 0.1% 123
2025
Q4
$395K Buy
872
+56
+7% +$24.1K 0.1% 122
2025
Q3
$320K Buy
816
+28
+4% +$11.7K 0.09% 124
2025
Q2
$351K Buy
788
+106
+16% +$48.8K 0.12% 95
2025
Q1
$331K Buy
682
+31
+5% +$14.4K 0.12% 96
2024
Q4
$262K Buy
651
+13
+2% +$6.03K 0.1% 104
2024
Q3
$297K Buy
638
+20
+3% +$9.61K 0.11% 101
2024
Q2
$290K Hold
618
0.11% 100
2024
Q1
$258K Buy
618
+15
+2% +$6.34K 0.1% 103
2023
Q4
$245K Hold
603
0.11% 109
2023
Q3
$210K Hold
603
0.09% 120
2023
Q2
$212K Buy
+603
New +$203K 0.09% 117

Other funds holding VRTX

Delta Financial Advisors's VRTX Position: Q1 2026 in Review

Delta Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1% in Q1 2026, selling an estimated $4.2K and leaving 863 shares worth $385K. The position accounts for 0.1% of the portfolio, ranked #123.

Delta Financial Advisors first reported a position in VRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $395K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Delta Financial Advisors held 863 shares of Vertex Pharmaceuticals worth $385K as of Q1 2026.
  • Delta Financial Advisors sold 9 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2K.
  • Vertex Pharmaceuticals made up 0.1% of Delta Financial Advisors's portfolio in Q1 2026, its #123 holding.
  • Delta Financial Advisors first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Delta Financial Advisors's Vertex Pharmaceuticals position peaked at $395K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Delta Financial Advisors's 13F filing for Q1 2026, filed 5 May 2026.